FIGURE 6.

Prevalence of selected acute and chronic conditions among Alabama Genomic Health Initiative participants. Conditions in which the treatment had a high‐level pharmacogenetic association were prioritized for inclusion, in addition to adverse effects of medical drugs. Conditions of interest that may be more actionable as further evidence emerges (e.g., diabetes), and those that may provide insight into the potential utility of pre‐emptive pharmacogenetic data for research and/or treatment for unseen circumstances (e.g., coronavirus disease 2019 [COVID‐19]) are presented. *For COVID, prevalence represents the number of participants who tested positive. Among participants who tested positive, 3.8% (6.8% of Black COVID (+) participants; 3.2% of White COVID (+) participants; 2.9% of women with COVID (+) participants; 6.9% of men with COVID (+) participants) had severe disease requiring intervention (e.g., mechanical ventilation). Psychiatric conditions include adjustment disorders, anxiety disorders, attention deficit disorders, delirium dementia/other cognitive disorders, mood disorders, personality disorders, schizophrenia, and other psychotic disorders. Cancer includes breast, colorectal, gastrointestinal cancers, leukemia, and lung cancer. Gastric conditions: gastroesophageal reflux disease and gastroparesis